Use of tetrapeptide-3 GEKG or pentapeptide-3 GEKGF for treating degenerative joint disease is disclosed. A pharmaceutical composition comprising an effective amount of tetrapeptide-3 GEKG or pentapeptide-3 GEKGF and a pharmaceutically acceptable carrier is also disclosed.